Category: Clinical Trials

All Podcast Categories
S3-E47 - What does the next year hold for the NAFLD metabolic disease link?

S3-E47 – What does the next year hold for the NAFLD metabolic disease link?

Surfers Roger Green, Jörn Schattenberg and Louise Campbell embark on their first exclusive discussion together in a while without any guest panelists. After several weeks of attending and reviewing conferences, the trio take the opportunity to talk about what the next year holds for the NAFLD-metabolic disease link.

S3-E46.5 - Discussing NITs and Final Thoughts on NAFLD Summit

S3-E46.5 – Discussing NITs and Final Thoughts on NAFLD Summit

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this final conversation, the group discusses NITs and what will change between now and when this conference convenes next year.

S3-E46.4 - Weight Change and Lifestyle Modification in Clinical Trials

S3-E46.4 – Weight Change and Lifestyle Modification in Clinical Trials

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group discusses the impact of weight change and lifestyle modification in clinical trials.

S3 E46.3 - Discussing Clinical Trial Design at the NAFLD Summit

S3 E46.3 – Discussing Clinical Trial Design at the NAFLD Summit

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group explores issues around clinical trial design, focusing specifically on the value of Phases 2a and 2b and whether improvement in patient self-management during trials is a research artifact or a replication of reality.

S3-E46.2 - NAFLD Summit in Context and Learning from Failed Trials

S3-E46.2 – NAFLD Summit in Context and Learning from Failed Trials

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group contextualizes and compares the NAFLD Summit to other major liver conferences and meetings. The group also assesses Session 9 from Friday, a series of case studies on why trials fail.

S3-E46.1 - Underreported Alcohol Use and Treating Comorbidities

S3-E46.1 – Underreported Alcohol Use and Treating Comorbidities

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group discusses underreported alcohol use in clinical trials and the impact of treating comorbidities on the treatment of NAFLD.

S3-E46 - A Review of the 2022 NAFLD Summit from Dublin

S3-E46 – A Review of the 2022 NAFLD Summit from Dublin

The 2022 NAFLD Summit proved to be an in-depth, successful conference brought to life by key opinion leaders in fatty liver and metabolic disease from around the world. In Season 3, Episode 46, Surfer Roger Green hosts a review on site in Dublin with presenting speakers Mazen Noureddin, Sven Francque and Hannes Hagström.

S3-E45.4 - Paris Review: NITs, Metabolic Disease and Final Thoughts

S3-E45.4 – Paris Review: NITs, Metabolic Disease and Final Thoughts

In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this final conversation, the group explores the rest of the Day Two program, focusing on the development of an NIT diagnostic pathway. Finally, each offers their closing remarks on being a part of the 8th Paris NASH Meeting and what the future looks like in this space.

S3-E45.3 - Paris Review: Session 5 on Clinical Trial Innovation

S3-E45.3 – Paris Review: Session 5 on Clinical Trial Innovation

In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this conversation, the group discusses presentations on adaptive trial strategies, trial recruitment and reducing screen fail rates, and the impact of educating patients on better self-care.

Experience Nudge Learning!
Interested in a new way of learning?